Last updated on April 16, 2014 at 11:32 EDT

Proteologics and Newcastle Innovation Enter Exclusive Agreement to Develop and Commercialize Therapeutics for Asthma and Other Respiratory Diseases

February 20, 2013

REHOVOT, Israel and NEWCASTLE, Australia, February 20, 2013 /PRNewswire/ –

Leading drug developer Proteologics Ltd. (TASE:PRTL) and Newcastle Innovation Limited,
the technology transfer company of the University of Newcastle, Australia, have entered
into an exclusive license agreement to develop and commercialize therapeutics for
respiratory and other diseases based on the novel target Midline-1, an E3 ubiquitin

University of Newcastle researchers* identified Midline-1 (also known as TRIM 18) as a
novel target that regulates airway inflammation and promotes allergen and
rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. These findings
were published in the January 2013 issue of Nature Medicine
[http://www.nature.com/nm/journal/v19/n2/full/nm.3049.html ].

A significant, potential advantage of a small molecule inhibitor of Midline-1 is that
it would be non-steroidal, thus overcoming the increasing resistance to current
steroid-based or other anti-inflammatory asthma treatments.

CEO of Proteologics Josh Levine commented: “We are excited to enter into this
agreement with Newcastle Innovation and, together with the University’s world-class
scientists, jointly develop therapeutics based on this novel target. Asthma represents a
large unmet medical need as there is currently no cure to treat the underlying cause of
the disease. Together, we hope to develop a treatment that could help patients suffering
from this debilitating, chronic disease.”

Newcastle Innovation CEO Dr Brent Jenkins said: “The agreement with Proteologics marks
a significant milestone in the evolution of laboratory discovery to proof-of-concept and
the development of effective therapeutics. We are proud of the achievements to date and
are confident new treatments will be available in the near future.”

About Asthma: Allergic asthma is an inflammatory disease of the conducting airways,
affecting an estimated 300 million people worldwide. Currently, there is no cure to treat
the underlying cause, but treatments exist to control or reduce symptoms. The disease
still remains under-treated due to various limitations in the use of existing drugs, like
steroidal overuse, and also factors like under-diagnosis and patient non-compliance.

About Proteologics: Proteologics [http://www.proteologics.com/index.htm ] is a leading
drug discovery company focusing on small molecule inhibitors of the ubiquitin system.
Professors Avram Hershko and Aaron Ciechanover, the 2004 Nobel Laureates for the discovery
of the ubiquitin system, are actively involved with the company and lead the company’s
Scientific Advisory Board. Proteologics has entered into a number of collaborations
including with GlaxoSmithKline (GSK) and leading labs around the world. Proteologics is a
public company, traded on the Tel Aviv Stock Exchange. Investors include GSK and leading
Israeli biotech companies and venture funds.

About Newcastle Innovation:Newcastle Innovation [http://newcastleinnovation.com.au ]
Ltd is the technology transfer company of the University of Newcastle and facilitates the
transfer of knowledge, technology and scientific research from the University to
commercial partners.

About the University of Newcastle: The University of Newcastle
[http://www.newcastle.edu.au ] is the most research intensive university outside of an
Australian capital city. Ranked in Australia’s top eight for research excellence,
Newcastle has a strong international reputation for innovation, excellence and research
with impact.

        - The research and clinical team was led by Professor Joerg Mattes, Chair of
          Paediatrics and Child Health at the University of Newcastle, Australia. Professor
          Mattes leads the Experimental and Translational Respiratory group at the Hunter
          Medical Research Institute's (HMRI [http://www.hmri.com.au ]) VIVA program and works
          as a Respiratory Paediatrician at the John Hunter Children's Hospital. HMRI is a
          partnership between the University of Newcastle, Hunter New England Local Health
          Network and the Community.

FURTHER INFORMATION: Avishai Levy, Proteologics, +972-8-9475666
avishai@proteologics.com| Dr Brent Jenkins, Newcastle Innovation, +61-2-4921-8777

SOURCE Proteologics Ltd

Source: PR Newswire